Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age

J Am Coll Cardiol 2022;80(1):1-18 doi: 10.1016/j.jacc.2022.04.040

In this analysis from EMPEROR-Preserved, empagliflozin delivered efficacy across all age groups, with similar effects seen in older patients with heart failure with preserved ejection fraction (HFpEF).